Overview

This trial is active, not recruiting.

Condition squamous cell carcinoma of the head and neck
Treatments abraxane, cetuximab, cisplatin, 5-fu, radiation (post induction)
Phase phase 2
Target EGFR
Sponsor Washington University School of Medicine
Start date October 2008
End date August 2010
Trial size 30 participants
Trial identifier NCT00736944, 08-0911 / 201105504

Summary

This phase two trial will determine the tumor response rate at the primary site and at involved regional nodes to two cycles of an IC regimen of weekly Abraxane and cetuximab given in combination with cisplatin and 5-FU in patients with local regionally advanced HNSCC.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Induction chemotherapy followed by Radiation therapy plus Cisplatin Induction chemotherapy: Abraxane 100 mg/m2 IVPB, Day 1, 8, and 15 of cycles 1, 2, and 3. Cetuximab 400 mg/m2 IVPB, Day 1, cycle 1. Cetuximab 250 mg/m2 IVPB, Day 8 and 15 cycle 1, 2 and 3. Cisplatin 75 mg/m2 IVPB, Day 1, cycles 1, 2, and 3. 5-FU 750 mg/m2 CIVI, Day 1, 2 and 3, cycles 1, 2, and 3. Post-Induction: Radiation - Monday-Friday weeks 1-7 with concurrent Cisplatin 100 mg/m2 IVPB on radiation day 1, 22, and 42.
abraxane
100 mg/m2 IVPB, Day 1, 8 and 15 of cycles 1, 2, and 3
cetuximab
400 mg/m2 IVPB, Day 1, cycle 1
cetuximab
250 mg IVPB, Day 8 and 15 cycle 1, Day 1, 8 and 15 of cycles 2 and 3
cisplatin
75 mg/m2 IVPB Day 1, cycles 1, 2 and 3
5-fu
750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
radiation (post induction)
Monday-Friday, weeks 1-7
cisplatin
(Post induction) Cisplatin 100 mg/m2 IVPB on radiation day 1, 22 and 42
(Experimental)
Induction chemotherapy followed by Radiation therapy plus Cetuximab Induction chemotherapy: Abraxane 100 mg/m2 IVPB, Day 1, 8, and 15 of cycles 1, 2, and 3. Cetuximab 400 mg/m2 IVPB, Day 1, cycle 1. Cetuximab 250 mg/m2 IVPB, Day 8 and 15 cycle 1, 2 and 3. Cisplatin 75 mg/m2 IVPB, Day 1, cycles 1, 2, and 3. 5-FU 750 mg/m2 CIVI, Day 1, 2 and 3, cycles 1, 2, and 3. Post-Induction: Radiation - Monday-Friday weeks 1-7 with concurrent Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB
abraxane
100 mg/m2 IVPB, Day 1, 8 and 15 of cycles 1, 2, and 3
cetuximab
400 mg/m2 IVPB, Day 1, cycle 1
cetuximab
250 mg IVPB, Day 8 and 15 cycle 1, Day 1, 8 and 15 of cycles 2 and 3
cisplatin
75 mg/m2 IVPB Day 1, cycles 1, 2 and 3
5-fu
750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
radiation (post induction)
Monday-Friday, weeks 1-7
cetuximab
(Post-induction) Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB

Primary Outcomes

Measure
Clinical Complete Response Rate at the Primary Tumor
time frame: post-2 cycles of induction (approximately 42 days from start of treatment)

Secondary Outcomes

Measure
Clinical Partial Response Rate at the Primary Tumor
time frame: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
Clinical Complete and Partial Response Rates to the Involved Regional Nodes
time frame: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
Clinical Overall Complete and Partial Response Rates
time frame: post-2 cycles of induction therapy (approximately 42 days)
Complete and Partial Response Rates of Primary Tumor by FDG Uptake on PET Scan
time frame: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
Complete and Partial Response Rates of Involved Lymph Nodes by FDG Uptake on PET Scan
time frame: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
Radiographic Complete and Partial Response Rates of Primary Tumor as Assessed by Conventional CT Scan Using RECIST Criteria
time frame: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
Radiographic Complete and Partial Response Rates of Involved Lymph Nodes as Assessed by Conventional CT Scan Using RECIST Criteria
time frame: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
Radiographic Overall Complete and Partial Response Rates as Assessed by Conventional CT Scan Using RECIST Criteria
time frame: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
Correlate Primary Tumor Site Response Rates Based on Visual Categorical Criteria of Assessment With That Based on CT Scan and FDG-PET/CT
time frame: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
Correlate Nodal Response Rates Based on Visual Categorical Criteria of Assessment With That Based on CT Scan and FDG-PET/CT
time frame: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
Correlate Overall Tumor Response Rates Based on Visual Categorical Criteria of Assessment With That Based on CT Scan and FDG-PET/CT
time frame: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
Correlate SPARC Expression by Immunohistochemistry (IHC) in Baseline Primary Tumor Tissue With Primary Tumor Site Complete Response Rate to Induction Chemotherapy
time frame: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
Correlate SPARC Expression by Immunohistochemistry (IHC) in Baseline Primary Tumor Tissue With Primary Tumor Site Partial Response Rate to Induction Chemotherapy
time frame: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
Correlate SPARC Expression (Intensity of Staining) by Immunohistochemistry (IHC) in Baseline Primary Tumor Tissue With Primary Tumor Site Complete Response Rate to Induction Chemotherapy
time frame: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
Correlate SPARC Expression (Intensity of Staining) by Immunohistochemistry (IHC) in Baseline Primary Tumor Tissue With Primary Tumor Site Partial Response Rate to Induction Chemotherapy
time frame: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
Adverse Events Experienced During Induction Chemotherapy in the First Ten Patients for a Pre-planned Safety Analysis
time frame: completion of the first 10 patients induction chemotherapy
Overall Survival
time frame: 10 years from completion of treatment
Disease Free Survival
time frame: 10 years from completion of treatment
Progression-free Survival
time frame: 10 years from completion of treatment

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion - Selected Stages 3 and 4a/b HNSCC: All patients must have T2-T4 primary tumors. Patients with T1 tumors will be excluded. Although most of these patients will have regional nodal disease, patients with no nodal disease will also be eligible. - Oropharynx, hypopharynx, larynx, and oral cavity sub-sites only. Patients with nasopharyngeal, sinus and other sub-sites of the head and neck, or unknown primary SCC of the head and neck will NOT be eligible. - Age ≥18 years - Signed informed consent. - ECOG Performance Status (PS) of 0-2 (Appendix 1). - Adequate vital organ function (serum creatinine < 1.8 mg/dl, total bilirubin /= 1500/ul, Platelets > 100,000/ul, HGB > 9.0 g/dl). - Patients with reproductive potential must use an effective method of contraception to avoid pregnancy for the duration of the trial and for three months after completing treatment. - If female of childbearing potential, the patient must have a negative pregnancy test. Exclusion Criteria: - Peripheral neuropathy > Grade 1. - Prior chemotherapy, EGFR targeted therapy or radiation therapy for HNSCC. - History of prior invasive malignancy diagnosed within the last three years other than local stage non-melanoma skin cancer. - Be taking cimetidine or allopurinol. Patients must discontinue taking the medication for one week before receiving treatment with Abraxane. - Be taking cimetidine or allopurinol. Patients must discontinue taking the medication for one week before receiving treatment with Abraxane.

Additional Information

Official title Trial to Determine the CR Rate at the Primary Tumor Site After 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head & Neck Carcinoma Treated With Definitive Concurrent Cisplatin & Radiation Therapy
Principal investigator Douglas Adkins, M.D.
Description Primary objective: To determine the clinical CR rate (CR-p) at the primary tumor site to an IC regimen of weekly Abraxane and cetuximab with CF (ACCF) given for two cycles (over 6 weeks) in patients with locally advanced non-metastatic HNSCC. The assessment of primary tumor site response will be performed by the treating physician by careful clinical examination using WHO criteria. Radiographic studies will also be performed to assess primary tumor site response but will be used primarily to confirm lack of disease progression that may not be detected based on clinical examination alone. The secondary objectives include: - Document the clinical PR rate (PR-p) at the primary tumor site with this IC regimen - Document the clinical CR and PR rates at the involved regional nodes (CR-n and PR-n) with this IC regimen - Document the clinical overall CR rate (CR-o) (defined as achievement of a CR at the primary tumor site and at the involved regional nodes) and the clinical overall PR rate (PR-o) with this IC regimen - Document the CR (CR-p, CR-n, and CR-o) and PR (PR-p, PR-n, and PR-o) rates by FDG uptake on PET scan after this IC regimen - Document radiographic CR (CR-p, CR-n, and CR-o) and PR (PR-p, PR-n, and PR-o) rates as assessed by conventional CT scan using RECIST criteria after this IC regimen. - Correlate primary tumor site, nodal and overall tumor response rates based on WHO criteria of assessment with that based on CT scan and FDG-PET/CT. - Document and quantify SPARC expression by IHC in primary tumor tissue obtained at baseline in each patient and attempt to correlate these results with primary tumor site response to ACCF. - Document and grade AE's with this IC regimen with a pre-planned safety analysis after the first ten patients have completed the IC regimen. - Determine the overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) of this patient population.
Trial information was received from ClinicalTrials.gov and was last updated in March 2015.
Information provided to ClinicalTrials.gov by Washington University School of Medicine.